experimental group:immunotherapy

4 trials

Sponsors

The First Affiliated Hospital of Anhui Medical University, Shandong Cancer Hospital, Beijing Cancer Hospital, The First Affiliated Hospital of Xiamen University

Conditions

Cardiac toxicityCervical cancerNasopharyngeal carcinomarenal cell carcinoma

Early Phase 1

Early Detection of chemotherapy Induced Cardiotoxicity by Cardiac Magnetic Resonance

Active, not recruitingChiCTR2000034807

The First Affiliated Hospital of Anhui Medical UniversityCardiac toxicity

Start: 2020-08-10Updated: 2020-07-27

Phase 2

An exploratory study of immunotherapy combined with stereotactic radiotherapy in oligometastatic renal cell carcinoma

RecruitingChiCTR2100047798

Shandong Cancer Hospitalrenal cell carcinoma

Start: 2021-03-01Updated: 2022-02-28

Open label, single arm, prospective phase II clinical trial protocol of Tegio rhythm chemotherapy combined with Carolizumab immunotherapy for locally advanced nasopharyngeal carcinoma with residual plasma EBV-DNA after induction chemotherapy

RecruitingChiCTR2500098668

The First Affiliated Hospital of Xiamen UniversityNasopharyngeal carcinoma

Start: 2023-12-04Updated: 2025-03-17

Unknown Phase

Sintilimab with induction chemotherapy and concurrent chemoradiotherapy in locally advanced cervical cancer

Active, not recruitingChiCTR2200056451

Beijing Cancer HospitalCervical cancer

Start: 2022-02-07Updated: 2024-10-15